Effect of Brimonidine on Retinal Ganglion Cell Survival in an Optic Nerve Crush Model

American Journal of Ophthalmology

Volumn 147, Issue 2, 2009, Pages 326-331

  Ma, Ke ^a   Xu, Liang ^a   Zhang, Haijuan ^a   Zhang, Shixian ^a   Pu, Mingliang ^a   Jonas, Jost B ^a,b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BRIMONIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DENSITY; CELL SURVIVAL; CONTROLLED STUDY; EYE; NEUROPROTECTION; NONHUMAN; OPTIC NERVE; OPTIC NERVE LESION; PRIORITY JOURNAL; RAT; RETINA GANGLION CELL; SPRAGUE DAWLEY RAT; SUPERIOR COLLICULUS;

ADRENERGIC ALPHA-AGONISTS; ANIMALS; CELL COUNT; CELL SURVIVAL; DISEASE MODELS, ANIMAL; INJECTIONS, INTRAPERITONEAL; NERVE CRUSH; NEUROPROTECTIVE AGENTS; OPTIC NERVE INJURIES; QUINOXALINES; RATS; RATS, SPRAGUE-DAWLEY; RETINAL GANGLION CELLS;

EID: 58249121841     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajo.2008.08.005     Document Type: Article

References (40)

1. Heijl A., Leske M.C., Bengtsson B., et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 120 (2002) 1268-1279
2. AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 12. Baseline risk factors for sustained loss of visual field and visual acuity in patients with advanced glaucoma. Am J Ophthalmol 134 (2002) 499-512
3. Miglior S., Torri V., Zeyen T., et al. Intercurrent factors associated with the development of open-angle glaucoma in the European Glaucoma Prevention Study. Am J Ophthalmol 144 (2007) 266-275
4. Yoles E., and Schwartz M. Potential neuroprotective therapy for glaucomatous optic neuropathy. Surv Ophthalmol 42 (1998) 367-372
5. Cui Q., Lu Q., So K.F., and Yip H.K. CNTF, not other trophic factors, promotes axonal regeneration of axotomized retinal ganglion cells in adult hamsters. Invest Ophthalmol Vis Sci 40 (1999) 760-766
6. Kurokawa T., Katai N., Sbibuki H., et al. BDNF diminishes caspase-2 but not c-jun immunoreactivity of neurons in retinal ganglion cell layer after transient ischemia. Invest Ophthalmol Vis Sci 40 (1999) 3006-3011
7. Solberg Y., Rosner M., Turetz J., and Belkin M. MK-801 has neuroprotective and antiproliferative effects in retinal laser injury. Invest Ophthalmol Vis Sci 38 (1997) 1380-1389
8. Kapin M.A., Doshi R., Scatton B., DeSantis L.M., and Chandler M.L. Neuroprotective effects of eliprodil in retinal excitotoxicity and ischemia. Invest Ophthalmol Vis Sci 40 (1999) 1177-1182
9. Freeman E.E., and Grosskreutz C.L. The effect of FK506 on retinal ganglion cells after optic nerve crush. Invest Ophthalmol Vis Sci 41 (2000) 1111-1115
10. Yasuyoshi H., Kashii S., Zhang S., et al. Protective effect of bradykinin against glutamate neurotoxicity in cultured rat retinal neurons. Invest Ophthalmol Vis Sci 41 (2000) 2273-2278
11. Wein F.B., and Levin L.A. Current understanding of neuroprotection in glaucoma. Curr Opin Ophthalmol 13 (2002) 61-67
12. Levkovitch-Verbin H., Kalev-Landoy M., Habot-Wilner Z., and Melamed S. Minocycline delays death of retinal ganglion cells in experimental glaucoma and after optic nerve transection. Arch Ophthalmol 124 (2006) 520-526
13. Martin K.R., Quigley H.A., Zack D.J., et al. Gene therapy with brain-derived neurotrophic factor as a protection: retinal ganglion cells in a rat glaucoma model. Invest Ophthalmol Vis Sci 44 (2003) 4357-4365
14. Yücel Y.H., Gupta N., Zhang Q., Mizisin A.P., Kalichman M.W., and Weinreb R.N. Memantine protects neurons from shrinkage in the lateral geniculate nucleus in experimental glaucoma. Arch Ophthalmol 124 (2006) 217-225
15. Zhong L., Bradley J., Schubert W., et al. Erythropoietin promotes survival of retinal ganglion cells in DBA/2J glaucoma mice. Invest Ophthalmol Vis Sci 48 (2007) 1212-1218
16. Liebgott T., Miollan M., Berchadsky Y., Drieu K., Culcasi M., and Pietri S. Complementary cardioprotective effects of flavonoid metabolites and terpenoid constituents of Ginkgo biloba extract (EGb 761) during ischemia and reperfusion. Basic Res Cardiol 95 (2000) 368-377
17. Ahlemeyer B., Junker V., Hühne R., and Krieglstein J. Neuroprotective effects of NV-31, a bilobalide-derived compound: evidence for an antioxidative mechanism. Brain Res 890 (2001) 338-342
18. Luo Y. Ginkgo biloba neuroprotection: Therapeutic implications in Alzheimer's disease. J Alzheimers Dis 3 (2001) 401-407
19. Soulié C., Nicole A., Christen Y., and Ceballos-Picot I. The Ginkgo biloba extract EGb 761 increases viability of hnt human neurons in culture and affects the expression of genes implicated in the stress response. Cell Mol Biol (Noisy-le-grand) 48 (2002) 641-646
20. Lee E.J., Chen H.Y., Wu T.S., Chen T.Y., Ayoub I.A., and Maynard K.I. Acute administration of Ginkgo biloba extract (EGb 761) affords neuroprotection against permanent and transient focal cerebral ischemia in Sprague-Dawley rats. J Neurosci Res 68 (2002) 636-645
21. Cheung Z.H., So K.F., Lu Q., et al. Enhanced survival and regeneration of axotomized retinal ganglion cells by a mixture of herbal extracts. J Neurotrauma 19 (2002) 369-378
22. Hoffman W.E., Kochs E., Werner C., Thomas C., and Albrecht R.F. Dexmedetomidine improves neurologic outcome from incomplete ischemia in the rat. Reversal by the alpha-2-adrenergic antagonist atipamezole. Anesthesiology 75 (1991) 328-332
23. Maier C., Steinberg G., Sun G., Zhi G., and Maze M. Neuroprotection by the alpha-2-adrenegic agonist dexmedetomidine in a focal model of cerebral ischemia. Anesthesiology 79 (1993) 306-312
24. Wen R., Cheng T., Li Y., Cao W., and Steinberg R. 2-Adrenergic agonists induce basic fibroblast growth factor expression in photoreceptors in vivo and ameliorate light damage. J Neurosci 16 (1996) 5986-5992
25. Yoles E., Wheeler L.A., and Schwartz M. α2-Adrenoreceptor agonists are neuroprotective in a rat model of optic nerve degeneration. Invest Ophthalmol Vis Sci 40 (1999) 65-73
26. Wheeler L.A., Lai R., and Woldemussie E. From the lab to the clinic: Activation of an alpha-2 agonist pathway is neuroprotective in models of retinal and optic nerve injury. Eur J Ophthalmol 1 (1999) S17-S21
27. Donello J.E., Padillo E.U., Webster M.L., Wheeler L.A., and Gil D.W. Alpha-2 adrenoceptor agonists inhibit vitreal glutamate and aspartate accumulation and preserve retinal function after transient ischemia. J Pharmacol Exp Ther 296 (2001) 216-223
28. WoldeMussie E., Ruiz G., Wijono M., and Wheeler L.A. Neuroprotection of retinal ganglion cells by brimonidine in rats with laser-induced chronic ocular hypertension. Invest Ophthalmol Vis Sci 42 (2001) 2849-2855
29. Mittag T.W., Danias J., Poborenec G., et al. Retinal damage after 3 to 4 months of elevated intraocular pressure in a rat glaucoma model. Invest Ophthalmol Vis Sci 41 (2000) 3451-3459
30. Pu M., and Berson D.M. A method for reliable and permanent intracellular staining of retinal ganglion cells. J Neurosci Methods 41 (1992) 45-51
31. Levkovitch-Verbin H., Harris-Cerruti C., Groner Y., Wheeler L.A., Schwartz M., and Yoles E. RGC death in mice after optic nerve crush injury: oxidative stress and neuroprotection. Invest Ophthalmol Vis Sci 41 (2000) 4169-4174
32. Wen R., Cheng T., Li Y., Cao W., and Steinberg R.H. Alpha 2-adrenergic agonists induce basic fibroblast growth factor expression in photoreceptors in vivo and ameliorate light damage. J Neurosci 16 (1996) 5986-5992
33. Misantone L.J., Gershenbaum M., and Murray M. Viability of retinal ganglion cells after optic nerve crush in adult rats. J Neurocytol 13 (1984) 449-465
34. Allcutt D., Berry M., and Sievers J. A qualitative comparison of the reactions of retinal ganglion cell axons to optic nerve crush in neonatal and adult mice. Brain Res 318 (1984) 231-240
35. Buys Y.M., Trope G.E., and Tatton W.G. (-)-Deprenyl increases the survival of rat retinal ganglion cells after optic nerve crush. Curr Eye Res 14 (1995) 119-126
36. Yoles E., and Schwartz M. Elevation of intraocular glutamate levels in rats with partial lesion of the optic nerve. Arch Ophthalmol 116 (1998) 906-910
37. Starke K. Regulation of noradrenaline release by presynaptic receptor systems. Rev Physiol Biochem Pharmacol 77 (1977) 45
38. Osborne N.N. Inhibition of cAMP production by alpha 2-adrenoceptor stimulation in rabbit retina. Brain Res 553 (1991) 84-88
39. Kent A.R., Nussdorf J.D., David R., Tyson F., Small D., and Fellows D. Vitreous concentration of topically applied brimonidine tartrate 0.2%. Ophthalmology 108 (2001) 784-787
40. Burke J., Manlapaz C., Kharlamb A., et al. Therapeutic use of 2-adrenoceptor agonists in glaucoma. In: Lanier S.M., and Limbird L.E. (Eds). 2-Adrenergic Receptors. Structure, Function and Therapeutic Implications (1996), Harwood Academic Publishers, Reading 179-187